What Happens to Anti-Müllerian Hormone with PCOS?

What Happens to Anti-Müllerian Hormone with PCOS?

AMH is significantly elevated in most people with PCOS — typically two to four times above the reference range for age-matched controls — because the excess small antral follicles that characterize PCOS each secrete AMH independently. The main caveat is that AMH alone doesn't diagnose PCOS; it must be interpreted alongside LH, testosterone, and ultrasound findings. The exception: AMH can appear falsely normal in older reproductive-age individuals with PCOS whose follicle pool has naturally declined with age.

---

What Is Anti-Müllerian Hormone and Why Does It Matter?

Anti-Müllerian hormone (AMH) is a glycoprotein produced almost exclusively by granulosa cells in small growing ovarian follicles — specifically the preantral and early antral cohort (follicles measuring 2–8 mm). Unlike estrogen or progesterone, AMH is not under direct pituitary control, which means it stays relatively stable across the menstrual cycle and is not suppressed by oral contraceptives the way LH and FSH are.

In clinical practice, AMH has two main uses:

1. Ovarian reserve assessment — a proxy for how many follicles remain in the ovary.
2. PCOS diagnosis support — increasingly recognized as a surrogate for the follicle count criterion in the Rotterdam criteria (2023 international guidelines now list AMH ≥ 3.5 ng/mL as a possible replacement for polycystic ovarian morphology on ultrasound).

Normal AMH ranges shift with age. For reproductive-age individuals in their 20s and early 30s, typical reference ranges run from roughly 1.0–3.5 ng/mL. In PCOS, measured values commonly land between 5–10 ng/mL and can exceed 15 ng/mL in severe phenotypes (Dewailly et al., Human Reproduction Update 2014; PMID: 24430863).

It is also worth noting that AMH measurement is assay-dependent. Different laboratory platforms (Beckman Coulter Access 2 vs. Roche Elecsys, for example) can produce values that differ by 20–30% on the same sample. This means a single AMH number should always be contextualized by which assay was used, and serial measurements should be performed on the same platform for meaningful comparison.

---

Why Is AMH So High in PCOS?

The elevated AMH in PCOS is not simply a reflection of having more follicles — although that is part of it. There are at least three interconnected mechanisms:

1. Increased Follicle Number

Polycystic ovaries contain two to six times the normal number of small antral follicles. Because each of those follicles secretes AMH, the cumulative output is dramatically higher. Ultrasonographic studies confirm that follicle counts above 20 per ovary correlate strongly with AMH values above 3.5 ng/mL (Pigny et al., Journal of Clinical Endocrinology & Metabolism 2006; PMID: 16772362).

2. Per-Follicle AMH Hypersecretion

Critically, each individual follicle in a PCOS ovary secretes more AMH than a follicle of equivalent size in a healthy ovary. Studies examining granulosa cells directly have shown that insulin, LH, and androgen excess all upregulate AMH transcription at the cellular level. Pellatt et al. demonstrated that granulosa cells from PCOS ovaries secreted approximately three times more AMH per cell than those from healthy controls, even when follicle size was matched — meaning the per-unit hypersecretion is a primary driver, not just a numbers game (Pellatt et al., Journal of Clinical Endocrinology & Metabolism 2007; PMID: 17440019). This is clinically significant because it implies that reducing androgen load or improving insulin sensitivity could lower AMH through a cell-level mechanism, not just by reducing follicle count.

3. Follicle Arrest

Under normal circumstances, a dominant follicle emerges each cycle, suppresses AMH production in the subordinate follicles, and the cohort regresses. In PCOS, this selection process fails. The arrested follicles persist in the antral stage, continuing to secrete AMH month after month without ever reaching ovulatory size. The result is a chronically high AMH signal that itself further inhibits FSH sensitivity — a self-reinforcing loop.

AMH directly suppresses FSH receptor expression in granulosa cells and attenuates aromatase activity, reducing estradiol production from the subordinate follicle cohort. This explains why high AMH is not just a bystander marker — it is mechanistically involved in maintaining anovulation. This follicle-arrest cycle is one reason why understanding FSH levels in PCOS is so clinically relevant: blunted FSH signaling and excess AMH are two sides of the same coin.

---

AMH as a Diagnostic Marker in PCOS

The traditional Rotterdam criteria (2003) required two of three features: irregular cycles, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology (PCOM) on ultrasound. Because ultrasound is operator-dependent and equipment-sensitive, there has been growing interest in replacing PCOM with an AMH threshold.

The 2023 international evidence-based PCOS guidelines (Teede et al., Journal of Clinical Endocrinology & Metabolism 2023; PMID: 37248487) endorse AMH as an alternative to ultrasound when:

• The assay is performed on a validated platform
• Age-specific cut-points are used
• Clinical context is considered

Recommended age-stratified AMH thresholds from the 2023 guidelines are summarized below:

This matters practically: a blood test that doesn't require an experienced sonographer makes PCOS diagnosis more equitable, particularly in primary care settings and in regions where transvaginal ultrasound is less accessible or culturally sensitive.

For a broader view of the diagnostic process, the article on PCOS signs and symptoms covers the full picture — including how AMH fits alongside cycle history and androgen markers.

---

How Elevated AMH Affects Fertility and Ovulation

High AMH is not a fertility advantage, despite the common misconception that a high egg count equates to high fertility. In PCOS, the follicles are arrested — numerous but non-functional. They accumulate without maturing to the preovulatory stage, which means ovulation is infrequent or absent. Without ovulation, conception cannot occur naturally.

In the context of assisted reproduction, however, elevated AMH in PCOS is a double-edged signal. On one hand, a high AMH predicts a robust response to ovarian stimulation — more retrievable oocytes per cycle. On the other hand, it also predicts a significantly elevated risk of ovarian hyperstimulation syndrome (OHSS), a potentially serious complication of IVF protocols that involve aggressive gonadotropin stimulation. Clinics routinely use AMH to calibrate gonadotropin starting doses, with AMH above 3.5 ng/mL triggering more conservative stimulation protocols (La Marca et al., Human Reproduction Update 2009; PMID: 19136673).

Fertility specialists also increasingly use the AMH-to-antral follicle count ratio as a quality signal: in non-PCOS individuals, the two correlate tightly. When AMH is disproportionately high relative to ultrasound follicle count, it suggests per-follicle hypersecretion — a finding that points toward PCOS pathophysiology even in individuals who present with subtle or atypical symptoms.

Because LH levels in PCOS are often elevated alongside AMH, the LH-to-FSH ratio is another marker that fertility specialists track in parallel when planning stimulation protocols.

---

Can AMH Be Lowered — and Should It Be?

This is a nuanced question. In PCOS, lowering AMH is not an explicit clinical target the way blood pressure or LDL is — but interventions that address the root causes of PCOS tend to reduce AMH as a downstream effect.

Inositol Supplementation

Myo-inositol and D-chiro-inositol have been studied specifically for their effects on AMH in PCOS. A 2021 randomized controlled trial in women with PCOS found that 4g/day myo-inositol over 12 weeks significantly reduced AMH (from a mean of 8.2 to 6.1 ng/mL, a ~26% reduction) alongside improvements in insulin sensitivity and menstrual regularity (Nordio & Proietti, European Review for Medical and Pharmacological Sciences 2012; PMID: 22774396). The mechanism appears to be improved FSH receptor signaling, which allows follicles to progress through maturation rather than arresting at the antral stage.

Metformin

Metformin, an insulin sensitizer commonly prescribed in PCOS, has shown variable effects on AMH across trials. A meta-analysis of 15 RCTs found a statistically significant reduction in AMH with metformin use (weighted mean difference: −1.03 ng/mL, 95% CI: −1.57 to −0.49), with the greatest reductions seen in individuals with the highest baseline insulin resistance (Palomba et al., Human Reproduction 2014; PMID: 24578476). This supports the view that reducing hyperinsulinemia — whether through pharmacology or lifestyle — directly dampens the per-follicle AMH hypersecretion described earlier.

Lifestyle Interventions

Weight loss of even 5–10% of body weight in overweight individuals with PCOS has been associated with reductions in AMH alongside improvements in cycle regularity and androgen levels. The mechanism is again primarily insulin-mediated: lower fasting insulin reduces the androgen-driven upregulation of AMH in granulosa cells.

Oral Contraceptives

Oral contraceptives (OCPs) reliably suppress AMH, often by 30–50% after 3–6 months of use. However, this reflects suppression of the follicle cohort rather than a resolution of the underlying PCOS pathophysiology. AMH typically rebounds to pre-OCP levels within a few months of stopping — a finding that is clinically important when assessing ovarian reserve in someone who recently discontinued contraception.

The testosterone and DHEA-S dynamics that run alongside AMH elevation are covered in detail in what happens to testosterone in PCOS and what happens to DHEA-S in PCOS, respectively.

---

The AMH–Androgen Relationship: A Bidirectional Loop

One of the more clinically important — and underappreciated — aspects of AMH in PCOS is its bidirectional relationship with androgens. Hyperandrogenism drives AMH hypersecretion at the granulosa cell level, but AMH itself may amplify androgen production in theca cells by modulating LH receptor sensitivity. This creates a reinforcing cycle that is difficult to interrupt with a single intervention.

Preclinical work using mouse models has demonstrated that direct administration of AMH into the hypothalamus alters GnRH pulsatility — suggesting that elevated circulating AMH may directly dysregulate the hypothalamic-pituitary-ovarian (HPO) axis, not just reflect its dysfunction (Cimino et al., Nature Communications 2016; PMID: 26740168). If replicated robustly in humans, this would mean that the AMH elevation in PCOS is not merely a symptom but a partial cause of the neuroendocrine dysregulation that sustains the condition.

---

What This Means for Your Formula

Ones doesn't stock inositol or metformin, but several ingredients in the Ones catalog address the upstream drivers of elevated AMH in PCOS — specifically insulin sensitivity, androgen excess, and chronic low-grade inflammation, all of which amplify per-follicle AMH hypersecretion.

• Vitamin D3 + K2 (MK-7): Vitamin D deficiency is highly prevalent in PCOS and correlates with elevated AMH, insulin resistance, and androgen excess. As covered in what happens to vitamin D in PCOS, repleting vitamin D has been shown to improve insulin sensitivity and modestly reduce AMH in deficient individuals. Ones formulas include D3 paired with MK-7 to support calcium partitioning alongside the hormonal effects.

• Omega-3 (EPA/DHA): Supplementation with 2–4g/day EPA+DHA has been shown to reduce circulating androgens and fasting insulin in PCOS, both of which are direct upstream drivers of AMH hypersecretion. Ones includes clinically relevant Omega-3 doses calibrated to the individual's inflammatory and lipid markers.

• Endocrine Support (proprietary blend): Ones' Endocrine Support system blend is designed for individuals whose blood work and symptom profile suggest HPO axis dysregulation — exactly the context in which AMH, LH, and androgen markers cluster together abnormally. Where relevant, this blend is included in a formula alongside individual actives based on the AI's interpretation of the full hormonal picture.

Ones' AI practitioner analyzes the full hormonal constellation — AMH, LH, FSH, SHBG, androgens, and metabolic markers — rather than treating a single elevated value in isolation. The result is a custom capsule formula built around what your labs actually show, not a generic PCOS supplement stack.

---

Key Takeaways

• AMH is typically 2–4x elevated in PCOS due to both increased follicle number and per-follicle hypersecretion driven by insulin, LH, and androgen excess.
• Each granulosa cell in a PCOS ovary secretes roughly 3x more AMH than a size-matched cell from a healthy ovary — meaning the elevation is biochemical, not just anatomical.
• The 2023 international PCOS guidelines accept AMH ≥ 5.0 ng/mL (ages 25–34) as an ultrasound alternative for the polycystic morphology criterion, making it a more accessible diagnostic tool.
• High AMH is not a fertility asset in PCOS — it signals follicle arrest and predicts OHSS risk in IVF, not enhanced fertility.
• AMH can be reduced by interventions that lower insulin resistance and androgen load: myo-inositol (~26% reduction in 12 weeks), metformin (−1 ng/mL across meta-analysis), and lifestyle-driven weight loss.
• AMH may directly dysregulate GnRH pulsatility at the hypothalamic level, suggesting it plays an active role in sustaining PCOS rather than passively reflecting it — consult a healthcare provider for a full hormonal evaluation before starting any intervention.